• Signed Informed Consent Form

• Age ≥18 years

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

• Histologically confirmed MZL. have a definite diagnosis of MZL

• Prior treatment with at least one line of systemic lymphoma including prior immunotherapy or chemoimmunotherapy

• At least one bi-dimensionally measurable nodal lesion (\> 1.5 cm in greatest diameter on CT scan or MRI) OR at least one bi-dimensionally measurable extranodal lesion (\> 1.0 cm in greatest diameter on CT scan or MRI)

• Need for systemic therapy as assessed by the investigator

• Life expectancy ≥ 3 months

• Adequate blood function (except for abnormalities considered by the investigator to be due to the underlying disease of lymphoma), defined as follows:

• Hemoglobin ≥ 7 g/dL; Absolute neutrophil count ≥ 1.0 × 109/L; Platelet count ≥ 50 x 109/L

⁃ Normal laboratory values:

⁃ Creatinine clearance ≥ 30 mL/min; Glutathione transaminase(AST) or glutathione aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN); Serum bilirubin ≤ 2 × ULN (≤ 3 × ULN in patients with Gilbert's syndrome)

⁃ For men who are not surgically sterile: Agree to use barrier contraception during treatment and for at least 3 months after the last dose of obinutuzumab or lenalidomide or as required by institutional guidelines, whichever is longer. In addition, male patients must agree to have their partner use an alternative method of contraception (e.g., oral contraceptive, intrauterine device, barrier method, or spermicide)

⁃ For women who are not surgically sterile: use two appropriate methods of contraception, such as oral contraceptives, intrauterine device, or barrier methods, in combination with spermicide for at least 28 days prior to agreeing to start of study medication, during treatment and for at least 12 months after the last dose of either obinutuzumab or lenalidomide, or as required by institutional guidelines, whichever is longer -